Menu
Recruiting NCT06858787

Validating CGM for GDM

No phase Interventional Gestational Diabetes Mellitus (GDM)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Continuous glucose monitor.
Who it may be relevant to
Registry conditions: Gestational Diabetes Mellitus (GDM). Basic parameters: 18 years — 50 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

The Validity of a Continuous Glucose Monitor in Diagnosing Gestational Diabetes: A Pilot Study

Overview

This is a prospective pilot study to assess the validity of using a continuous glucose monitor (CGM) in diagnosing gestational diabetes mellitus (GDM). Pregnant individuals between the ages of 18-50 years old receiving prenatal care at Mount Sinai Hospital (e..g, E-Level clinic and Faculty Practice Associates) will be enrolled. Potential participants will be approached during their prenatal care appointments. Participants will complete an informed consent form for the study during their standard-of-care prenatal appointments at our institution.

Interventions

  • Device Continuous glucose monitor
    Device is a remote sensor applied to the upper extremity that continuously samples glucose of interstitial fluid and uploading results to a mobile application.

Primary outcome measures

  • Blood glucose from CGM [Time frame: 10 days from sensor application to completion of testing]
  • Glucose Tolerance Test (GTT) values [Time frame: 1 hour and 3 hours]
  • Postpartum blood glucose [Time frame: 4 hours after childbirth]

Eligibility criteria

Inclusion criteria

  • Ages 18-50
  • Singleton pregnancy between 24-32 weeks gestational age
  • Prenatal care and delivery at Mount Sinai Hospital

Exclusion criteria

  • Multiple fetal gestation
  • Preexisting diabetes
  • Concurrent use of steroids
  • Anomalous fetus
  • Insufficient prenatal care (identified as missing half the recommended visits or establishing care after 20 weeks gestation)
  • Unable to tolerate oral glucose test

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Diagnostic

Study locations

United States · 2 centers
  • Icahn School of Medicine at Mount Sinai — New York
  • Mount Sinai South Nassau — Oceanside

Identifiers

NCT: NCT06858787 · STUDY-25-00172

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗